noc-18 and Pain

noc-18 has been researched along with Pain* in 2 studies

Other Studies

2 other study(ies) available for noc-18 and Pain

ArticleYear
Rapid development of nitric oxide-induced hyperalgesia depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model.
    Brain research, 1998, May-11, Volume: 792, Issue:2

    Intrathecal injection of a nitric oxide releasing compound, NOC-18, was used to define the role of nitric oxide (NO) in the spinal mechanism of neuropathic pain caused by unilateral chronic constriction injury to rat sciatic nerves. Paw withdrawal latency was used to evaluate nociception induced by thermal stimuli before surgery and afterwards at 1, 3, and 6 h, and on days 1, 2, 3, 4, 5, 8, and 12 after the nerve ligature. In the sham-surgery control groups, intrathecal injection of 10 or 100 microg of NOC-18 did not produce any change in withdrawal latencies. In rats with unilateral nerve ligation, however, administration of 1 or 10 microg, but not 0.1 microg, of NOC-18 significantly shortened the time in which thermal hyperalgesia developed after nerve injury. Injection of 1 microg of NOC-18 decreased the onset time of thermal hyperalgesia from 2 days to 3 h and with 10 microg hyperalgesia developed within 1 h after the nerve injury. The effects of intrathecal injection of MK-801, a N-methyl-D-aspartate (NMDA) receptor antagonist, N-nitro-L-arginine methyl ester (L-NAME), a NO synthase inhibitor, methylene blue (MB), a soluble guanylate cyclase inhibitor, and hemoglobin (Hb), a NO scavenger, on the development of thermal hyperalgesia after the sciatic nerve ligature were examined in the presence and absence of 1 and 10 microg of NOC-18. Acceleration of the development of thermal hyperalgesia induced by 1 and 10 microg NOC-18 was completely inhibited by Hb, but was not affected by either MK-801, L-NAME or MB. These findings indicate that NO plays an important role in the rapid development of thermal hyperalgesia after the nerve injury, but that facilitation of nociceptive processing in the spinal cord may entail an alternate to the NO-cyclic guanosine 3',5'-monophosphate (cGMP) pathway.

    Topics: Animals; Antidotes; Cyclic GMP; Disease Models, Animal; Dizocilpine Maleate; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Hemoglobins; Hot Temperature; Hyperalgesia; Ligation; Male; Methylene Blue; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroso Compounds; Pain; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Spinal Cord

1998
A new nitric oxide donor, NOC-18, exhibits a nociceptive effect in the rat formalin model.
    Journal of the neurological sciences, 1996, Sep-15, Volume: 141, Issue:1-2

    The utility of a new nitric oxide (NO) donor, NOC-18, and the contribution of the neurotransmitter NO to nociception in response to tissue injury in rats, were examined following the subcutaneous injection of formalin into the hindpaw. This model induces biphasic responses in pain-related behavior, such that C-fiber activation during the first phase triggers a state of central sensitization characterized by the second phase. Formalin-induced nociceptive behavior was facilitated by intracerebroventricular administration of NOC-18 in the second phase, but not the first phase. This enhancement was completely abolished by the soluble guanylate cyclase inhibitor, methylene blue. These findings indicate that NO causes nociception via the NO-cGMP pathway in the central nervous system and NOC-18 proved to be a convenient and useful tool for the investigation of nociception-related NO.

    Topics: Animals; Antidotes; Behavior, Animal; Formaldehyde; Injections, Intraventricular; Injections, Subcutaneous; Male; Methylene Blue; Motor Activity; Nitric Oxide; Nitroso Compounds; Nociceptors; Pain; Rats; Rats, Sprague-Dawley

1996